111 related articles for article (PubMed ID: 18281546)
1. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
Gururangan S; Turner CD; Stewart CF; O'Shaughnessy M; Kocak M; Poussaint TY; Phillips PC; Goldman S; Packer R; Pollack IF; Blaney SM; Karsten V; Gerson SL; Boyett JM; Friedman HS; Kun LE
Clin Cancer Res; 2008 Feb; 14(4):1124-30. PubMed ID: 18281546
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
Fouladi M; Blaney SM; Poussaint TY; Freeman BB; McLendon R; Fuller C; Adesina AM; Hancock ML; Danks MK; Stewart C; Boyett JM; Gajjar A
Cancer; 2006 Nov; 107(9):2291-7. PubMed ID: 17019740
[TBL] [Abstract][Full Text] [Related]
4. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Bagatell R; Gore L; Egorin MJ; Ho R; Heller G; Boucher N; Zuhowski EG; Whitlock JA; Hunger SP; Narendran A; Katzenstein HM; Arceci RJ; Boklan J; Herzog CE; Whitesell L; Ivy SP; Trippett TM
Clin Cancer Res; 2007 Mar; 13(6):1783-8. PubMed ID: 17363533
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Giles F; Verstovsek S; Faderl S; Vey N; Karp J; Roboz G; Khan KD; Cooper M; Bilgrami SF; Ferrant A; Daenen S; Karsten V; Cahill A; Albitar M; Kantarjian H; O'Brien S; Feldman E
Leuk Res; 2006 Dec; 30(12):1591-5. PubMed ID: 16574225
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.
Aquino VM; Weitman SD; Winick NJ; Blaney S; Furman WL; Kepner JL; Bonate P; Krailo M; Qu W; Bernstein M
J Clin Oncol; 2004 Apr; 22(8):1413-9. PubMed ID: 15084615
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Gururangan S; Petros WP; Poussaint TY; Hancock ML; Phillips PC; Friedman HS; Bomgaars L; Blaney SM; Kun LE; Boyett JM
Clin Cancer Res; 2006 Mar; 12(5):1540-6. PubMed ID: 16533779
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
Badruddoja MA; Penne K; Desjardins A; Reardon DA; Rich JN; Quinn JA; Sathornsumetee S; Friedman AH; Bigner DD; Herndon JE; Cahill A; Friedman HS; Vredenburgh JJ
Neuro Oncol; 2007 Jan; 9(1):70-4. PubMed ID: 17108065
[TBL] [Abstract][Full Text] [Related]
13. Cloretazine for the treatment of acute myeloid leukemia.
Vey N; Giles F
Expert Rev Anticancer Ther; 2006 Mar; 6(3):321-8. PubMed ID: 16503849
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of imexon in patients with advanced malignancy.
Dragovich T; Gordon M; Mendelson D; Wong L; Modiano M; Chow HH; Samulitis B; O'Day S; Grenier K; Hersh E; Dorr R
J Clin Oncol; 2007 May; 25(13):1779-84. PubMed ID: 17470869
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
MacDonald TJ; Stewart CF; Kocak M; Goldman S; Ellenbogen RG; Phillips P; Lafond D; Poussaint TY; Kieran MW; Boyett JM; Kun LE
J Clin Oncol; 2008 Feb; 26(6):919-24. PubMed ID: 18281665
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
Horton TM; Blaney SM; Langevin AM; Kuhn J; Kamen B; Berg SL; Bernstein M; Weitman S
Clin Cancer Res; 2005 Mar; 11(5):1884-9. PubMed ID: 15756014
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies.
Geoerger B; Doz F; Gentet JC; Mayer M; Landman-Parker J; Pichon F; Chastagner P; Rubie H; Frappaz D; Le Bouil A; Gupta S; Vassal G
J Clin Oncol; 2008 Sep; 26(27):4394-400. PubMed ID: 18802151
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.
Murren J; Modiano M; Kummar S; Clairmont C; Egorin M; Chu E; Sznol M
Invest New Drugs; 2005 Mar; 23(2):123-35. PubMed ID: 15744588
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
